Login
$APYX
$2.65 -$0.16 (5.69%) Live

$APYX SEC Filings

Filed On Filing
05 Nov 2026 FORM 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

CLEARWATER, FL — November 5, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported fina...

28 Oct 2026 SCHEDULE 13G
29 Sep 2026 8-K: Other Events

Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance

07 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purposes of the Apyx Medical Corporation 2026 Share Incentive Plan (the “Plan”) are to: (i) aid in maintaining and developing key employees capable of assuring the future success of Apyx Medical Corporation (the “Company”), and to of...

06 Aug 2026 FORM 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

CLEARWATER, FL — August 6, 2026 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financ...

24 Jul 2026 8-K: Other Events

On July 24, 2026, the Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) reconstituted the membership and chairs of its standing committees as described below.

21 Jul 2026 SCHEDULE 13G/A
02 Jul 2026 Form 4: Waldman Lawrence, Director

Received 12,000 shares by exercise or conversion ($22.6K) · Gave up 5,024 shares to cover exercise price or tax ($22.6K)

26 Jun 2026 Proxy statement: annual meeting on August 6, 2026

CEO pay $1.2M, up 26% · say-on-pay vote

17 Jun 2026 Form 4: Roman Shawn David, Chief Operating Officer

Received 15,000 shares by exercise or conversion ($48.5K) · Gave up 10,533 shares to cover exercise price or tax ($48.5K)

17 Jun 2026 8-K: Entry into a Material Definitive Agreement

This letter agreement (this “Agreement”) confirms the terms of your appointment as Executive Chairman of Apyx Medical Corporation, a Delaware corporation (the “Company”), and the grant to you of restricted stock units (“RSUs”), under the...

15 Jun 2026 Form 4: Levine Wendy Lauren, Director

Granted 50,000 Stock Option (Option to Buy)

15 Jun 2026 Form 4: Vizirgianakis Stavros G., Director

Received 450,000 shares as a grant or award

15 Jun 2026 Form 4: Goodwin Charles D. Ii, Director

Granted 213,948 Stock Option (Option to Buy)

15 Jun 2026 Form 4: Roman Shawn David, Chief Operating Officer

Granted 88,044 Stock Option (Option to Buy)

15 Jun 2026 Form 4: Baylor-Henry Minnie, Director

Granted 50,000 Stock Option (Option to Buy)

15 Jun 2026 Form 4: Waldman Lawrence, Director

Granted 50,000 Stock Option (Option to Buy)

15 Jun 2026 Form 4: Hill Matthew C, Chief Financial Officer

Granted 132,066 Stock Option (Option to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support